Elutia's book value per share for the quarter that ended in Mar. 2026 was $0.51.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Elutia was 57.10% per year. The lowest was 57.10% per year. And the median was 57.10% per year.
Elutia's current price is $0.9513. Its book value per share for the quarter that ended in Mar. 2026 was $0.51. Hence, today's PB Ratio of Elutia is 1.87.
During the past 8 years, the highest P/B Ratio of Elutia was 15.00. The lowest was 0.99. And the median was 6.60.
Elutia (NAS:ELUT) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Elutia Book Value per Share Related Terms
Elutia Book Value per Share Historical Data
* Premium members only.
The historical data trend for Elutia's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELUT vs NSYS, MYO, SRTS: Book Value per Share Comparison
For the Medical Devices subindustry, Elutia's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elutia PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elutia's PB Ratio distribution charts can be found below:
* The bar in red indicates where Elutia's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elutia (ELUT) has a Book Value per Share of $0.51 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Elutia and its competitors.
Is Elutia's Book Value per Share too high?
Elutia's current Book Value per Share is $0.51. Overall, Elutia has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Elutia's Book Value per Share compare to NSYS and MYO?
Elutia's Book Value per Share of $0.51 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Medical Devices & Instruments company?
A good Book Value per Share depends on the Medical Devices & Instruments industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Elutia and its competitors. Elutia's current Book Value per Share is $0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elutia stock overvalued right now?
Based on GuruFocus' analysis, Elutia (ELUT) is currently considered Fairly Valued. The stock's GF Value™ is $0.91, compared to a current price of $0.95 — trading 4.5% above its estimated fair value. The current Book Value per Share is $0.51. Elutia's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Elutia (ELUT), the current Book Value per Share is $0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elutia (ELUT) Overvalued in 2026?
Based on GuruFocus' analysis, Elutia stock appears to be overvalued.
The current stock price of $0.95 is trading 4.5% above its estimated GF Value™ of $0.91.
GuruFocus considers Elutia to be Fairly Valued.
Key valuation signals for ELUT:
Book Value per Share: $0.51
GF Value™: $0.91 vs. price of $0.95 (4.5% above fair value)
No single metric tells the full story. See the ELUT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
36GF Score
Get the complete analysis for ELUT
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELUT has been successfully added to your 
